• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gilead Sciences

Senate drug price hearing turns into debate over healthcare reform

June 19, 2017 By Sarah Faulkner

Prescription drugs

Members of the Senate Health, Education, Labor and Pensions committee gathered last week to discuss the rising costs of prescription drugs. But the hearing quickly morphed into a heated back-and-forth between senators over the Republican’s efforts to reform healthcare. Democratic senators, including Sens. Patty Murray (D-Wash.) and Chris Murphy (D-Conn.), used their time to criticize […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Gilead Sciences

Pharma stocks fall on Trump’s proposal to cut NIH budget

March 16, 2017 By Sarah Faulkner

Pharma stocks fall on Trump's proposal to cut NIH budget

The Trump budget plan to slash more than 18% from the budget for the National Institutes of Health sent pharmaceutical stocks down today on Wall Street as investors reacted to the proposal. The budget proposal, released today, would cut the NIH budget by $5.8 billion, to $25.9 billion – an 18.3% cut. The proposal would also introduce […]

Filed Under: Featured, Policy, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Becton Dickinson, Biogen Idec, Boston Scientific, C.R. Bard, Gilead Sciences, johnsonandjohnson, Medtronic, Merck, Pfizer Inc.

Tax holiday could ignite more pharma M&A

December 6, 2016 By Sarah Faulkner

Capitol Hill

(Reuters) – U.S. President-elect Donald Trump’s plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth. For years, big U.S. drugmakers have turned to acquisitions of foreign companies to put their overseas cash to work, […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Amgen, Apple, Biogen Idec, Bristol-Myers Squibb Co., Eli Lilly & Co., Gilead Sciences, johnsonandjohnson, Pfizer Inc.

Tests to begin for HIV therapy injections, long-acting implants

November 29, 2016 By Sarah Faulkner

Drugs from companies, such as GlaxoSmithKline (NYSE:GSK), Gilead Sciences (NSDQ:GILD) and Merck (NYSE:MRK), are reportedly being considered for large-scale trials evaluating injectable HIV prevention therapies. Eventually, researchers hope to produce matchstick-sized implants that could provide year-long protection to vulnerable populations. Foster City, Calif.-based Gilead has a once-daily pill, Truvada, which prevents HIV infection during sex. Pre-exposure prophylaxis, also known […]

Filed Under: Drug-Device Combinations, Featured, Implants, Preclinical Trials, Research & Development Tagged With: Gilead Sciences, GlaxoSmithKline plc, Merck

  • « Go to Previous Page
  • Page 1
  • Page 2

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS